AB0090

PREVALENCE OF OSTEOPOROSIS IN ITALIAN POSTMENOPAUSAL WOMEN ACCORDING TO DEFRA ALGORITHM

A. M. Lurati1, A. Laria1, L. Castelanova2, P. Faggioni2, A. Tamburello2, A. Mazzone1, *Rheumatology Unit Fornaroli Hospital Magenta Italy; Magenta, Italy; ‡Internal Medicine Unit, Ospedale Civile, Legnano, Italy

Background: Osteoporosis is a recognized health problem and the burden of the disease is mostly associated with the occurrence of hip and vertebral fracture.

Objectives: This study was aimed at evaluating the prevalence of osteoporosis in Italian postmenopausal women, defined by DeFRA calculation as a 10 years fracture risk equal or higher than 20%.

Methods: This is a monocenter cohort study evaluating 1850 post-menopausal women aged 50 years and older. All the participants were evaluated as far as anthropometrics. Defra questionnaire was administered and calculated with bone mineral density (DXA) measured at lumbar spine and femoral neck.

Results: The prevalence of osteoporosis as assessed by DeFRA was 29.8% in the whole population, according to literature. The frequency of a risk fracture equal or higher than 20% varied from 7.9% in the group aged 50-59 years to 35% in subjects aged >80. Among clinical risk factors for fracture, the presence of a previous fracture (spine primarily) was the most commonly observed.

Conclusion: Our data showed that about one third of post-menopausal women aged 50 and older in Italy has osteoporosis on the basis of DeFRA algorithm, with a high 10 years fracture risk. A previous fracture is the most common risk factor. The data should be considered in relation to the need to increase prevention strategies and therapeutic intervention.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.3821

AB0092

BONE HEALTH IN PATIENTS WITH JUVENILE ONSET DERMATOMYOSITIS ASSESSED AFTER LONG-TERM FOLLOW-UP: A CASE CONTROL STUDY

H. Marstein1,2,5, K. Godang1,2, I. Sjaastad1,3,6, J. Bollerslev3,4, H. Sanner2,5, 1Rheumatology Unit Fornaroli Hospital Magenta Italy, Magenta, Italy; 2Internal Medicine Unit, Ospedale Civile, Legnano, Italy; 3Faculty of Medicine; University of Oslo, Oslo, Oslo, Norway; 4Dept of Endocrinology; Oslo University Hospital, Rikshospitalet, Oslo, Norway; 5Dept of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; 6Dept of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway

Background: Patients with juvenile dermatomyositis (JDM) are at risk of developing low bone mineral density (BMD) and not reach peak bone mass, mainly due to prednisolone (pred) treatment [1], making them prone to osteoporotic fractures later in life.

Objectives: To compare BMD in long-term JDM patients (Pts) with that of controls (Ctr) and in Pts explore how disease variables affect BMD.

Methods: Pts (n=59) were clinically examined median 16.8y (range 6.6 - 27.0y) after disease onset and compared 1:1 with age/sex matched Ctr. Dual-energy X-ray absorptiometry (DXA) was used to measure BMD and Z-scores in whole body (WB), lumbar spine at L2-L4 (spine), and pred use at follow up (R`s = -0.40 †† and -0.37 †) in Pts ≥20y.

Results: A positive moderate association between Z-score PR and BMD was found in Pts ≥20y (R` = 0.40 ††). In those ≥20y; also proximal (PR) and distal 1/3 radius (DIST), and total hip were examined. Pred at follow up was reported, and cumulative dose calculated. Bone remodeling factors: C-terminal telopeptide (CTX), amino-terminal propeptide (P1NP) and 25(OH) Vitamin D (25-D) were measured in serum.

Results: BMD was lower in Pts than Ctr, and both WB and spine BMD and Z-scores were lower in Pts <20y compared to Ctr (Table 1). The levels of vitamin D were 31±14ng/ml with a normal distribution and without any significant difference between primary care and rheumatology patients.

Conclusion: We found that Pts bone health was affected differently in young and adult JDM-Pts. Association analysis between BMD, Z-scores and medi-cal factors for bone remodeling were not conclusive. We will perform linear regression analysis to determine if and how BMDs and Z-scores are dependent on pred use, time and doses, and factors important for bone remodeling.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.5357

Table 1. Characteristics, disease variables, BMD and Z-scores in JDM Pts and Ctr

<table>
<thead>
<tr>
<th></th>
<th>Pts (n=28)</th>
<th>Pts ≥20y (n=11)</th>
<th>Ctr (n=28)</th>
<th>Ctr ≥20y (n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>21.5</td>
<td>15.3</td>
<td>21.4</td>
<td>14.4</td>
</tr>
<tr>
<td>Height, cm</td>
<td>164.9 (14.7)</td>
<td>171.8 (9.1)</td>
<td>159.8 (18.3)</td>
<td>174.0 (9.2)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>22.3 (4.8)</td>
<td>24.0 (4.4)</td>
<td>16.5 (11.6)</td>
<td>16.5 (11.6)</td>
</tr>
<tr>
<td>BMD, g/cm²</td>
<td>-0.76 (1.0)</td>
<td>-0.93 (1.2)</td>
<td>0.06 (1.3)</td>
<td>-0.93 (1.2)</td>
</tr>
<tr>
<td>Z-score WB</td>
<td>-0.39 (1.2)</td>
<td>-0.40 (1.2)</td>
<td>-0.19 (1.2)</td>
<td>-0.40 (1.2)</td>
</tr>
<tr>
<td>Z-score spine</td>
<td>-0.39 (1.0)</td>
<td>-0.40 (1.0)</td>
<td>-0.19 (1.0)</td>
<td>-0.40 (1.0)</td>
</tr>
<tr>
<td>Dist radius</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Dist radius</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

AB0093

VITAMIN D LEVELS IN PRIMARY CARE AND RHEUMATOLOGY PATIENTS

H. D. Marta1, A. Garcia Dorta1, C. Luis Zárata1, S. Bustabad1, F. Díaz-Gonzalez2, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain

Background: Although many studies are calling into question the benefits commonly attributed to the vitamin D out of the bone sphere, in the recent years its determination and supplementation has been generalized in the population. Causes of this trend are not clear, but generalist media pressure or even specialized over patients and doctors, along with overrated normality levels could be contributing to this fact. Actual literature[3-5] indicates that 25-OH vitamin D levels of 30ng/ml or higher are not necessary, and most of the authors agree that 20ng/ml levels are enough for the general population, and only levels below 12.5ng/ml must be considered deficient and subsidiaries of supplementation.

Objectives: Obtain the vitamin D levels distribution from a sample of individuals with no bone pathology, or supplementation prescription in Tenerife’s North Area.

Methods: Retrospective descriptive study of the 25-OH vitamin D levels requests from the Tenerife’s North Area, made for any reason by the Primary Care Doctor or the rheumatologist, both in the Primary Care Centers and the Hospital University of Canarias (HUC). 25-OH vitamin D values were gathered from 2662 blood samples from a total of 2635 patients, from September to November of 2018 (2241 from Primary Care and 421 from rheumatology). In order to determine the use of calcium and vitamin D supplements, and the presence of bone pathology, either renal or from a malabsorptive process, 400 individuals were randomly (250 from primary care and 150 from rheumatology). Demographic data (age and gender), calcium serum, phosphorus and 25-OH Vitamin D levels were gathered for the individual records. With regards to the treatment, data about vitamin D supplements, calcium with vitamin D, or the sum of both, that the patient may have in electrical prescriptions at that time; as well as osteoporosis treatment (biphosphonates, denosumab or teriparatide) were gathered.

Results: Using the age, gender, male/female relation, the levels of vitamin D, calcium and phosphorus, as comparison factors; the characteristics of the random population were statistically indistinguishable from the global population. Regarding the random sample characteristics, from the 150 rheumatology patients, 11 were men (7.3%) and 139 women (92.7%). While from the 250 primary care patients, 66 were men (26.4%) and 184 were women (73.6%). The average age of the primary care sample was 55.76±19.72 years and 65.16±13.84 years in the rheumatology sample.

In the total random healthy population: without bone pathology, renal or malabsorptive and without calcium, vitamin D or antiresorptive drug (n=181), the levels of vitamin D were 31±14ng/ml with a normal distribution and without clear differences between the primary care and rheumatology patients. When the healthy population distribution was studied by vitamin D levels, the 55% presented values below 30ng/ml, 12% below 20ng/ml and 4% showed levels under 12.5ng/ml levels agreed as deficient (see graph).

Conclusion: The 55% of the patients studied in primary care and rheumatology, without renal, digestive or bone disease and without vitamin D supplement,